

# Pierre Bedossa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6457146/publications.pdf>

Version: 2024-02-01

219  
papers

29,532  
citations

5268

83  
h-index

5120

166  
g-index

226  
all docs

226  
docs citations

226  
times ranked

25369  
citing authors

#	ARTICLE	IF	CITATIONS
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	3.7	2,171
2	Sampling variability of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2003, 38, 1449-1457.	7.3	1,690
3	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor $\alpha$ and $\beta$ , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5.	1.3	847
4	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 394, 2184-2196.	13.7	818
5	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019, 156, 1717-1730.	1.3	777
6	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , 2017, 66, 1022-1030.	3.7	734
7	Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. <i>Hepatology</i> , 2012, 56, 1751-1759.	7.3	657
8	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
9	Increased Infiltration of Macrophages in Omental Adipose Tissue Is Associated With Marked Hepatic Lesions in Morbid Human Obesity. <i>Diabetes</i> , 2006, 55, 1554-1561.	0.6	513
10	Fibrosis in Human Adipose Tissue: Composition, Distribution, and Link With Lipid Metabolism and Fat Mass Loss. <i>Diabetes</i> , 2010, 59, 2817-2825.	0.6	511
11	Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2014, 60, 565-575.	7.3	491
12	Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis. <i>Gastroenterology</i> , 2008, 134, 416-423.	1.3	475
13	Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis. <i>Hepatology</i> , 2009, 49, 851-859.	7.3	473
14	Sources of variability in histological scoring of chronic viral hepatitis. <i>Hepatology</i> , 2005, 41, 257-264.	7.3	471
15	High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2001, 34, 738-744.	7.3	461
16	Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. <i>Liver International</i> , 2009, 29, 242-247.	3.9	432
17	A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. <i>Journal of Hepatology</i> , 2013, 59, 550-556.	3.7	421
18	Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. <i>Hepatology</i> , 2009, 49, 1151-1157.	7.3	414

#	ARTICLE	IF	CITATIONS
19	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	8.1	411
20	A comparison of fibrosis progression in chronic liver diseases. <i>Journal of Hepatology</i> , 2003, 38, 257-265.	3.7	401
21	Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study). <i>Journal of Hepatology</i> , 2010, 53, 1013-1021.	3.7	386
22	Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. <i>Genome Biology</i> , 2008, 9, R14.	9.6	372
23	A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. <i>Journal of Hepatology</i> , 2016, 65, 579-588.	3.7	371
24	A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. <i>Hepatology</i> , 2012, 56, 532-543.	7.3	354
25	A Single-Center Surgical Experience of 122 Patients With Single and Multiple Hepatocellular Adenomas. <i>Gastroenterology</i> , 2009, 137, 1698-1705.	1.3	347
26	Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C. <i>Gastroenterology</i> , 2008, 135, 821-829.	1.3	309
27	Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. <i>Journal of Hepatology</i> , 2010, 52, 652-657.	3.7	300
28	Liver biopsy: The best, not the gold standard. <i>Journal of Hepatology</i> , 2009, 50, 1-3.	3.7	289
29	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021, 385, 1547-1558.	27.0	284
30	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	3.7	279
31	Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. <i>Human Pathology</i> , 2001, 32, 327-332.	2.0	268
32	Changing trends in malignant transformation of hepatocellular adenoma. <i>Gut</i> , 2011, 60, 85-89.	12.1	263
33	CMV drives clonal expansion of NKG2C <sup>+</sup> NK cells expressing self-antigen-specific KIRs in chronic hepatitis patients. <i>European Journal of Immunology</i> , 2012, 42, 447-457.	2.9	261
34	Impact of Interferon Alfa-2b and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C. <i>Hepatology</i> , 2000, 32, 1131-1137.	7.3	257
35	Pathology of non-alcoholic fatty liver disease. <i>Liver International</i> , 2017, 37, 85-89.	3.9	247
36	Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. <i>Journal of Hepatology</i> , 2015, 62, 848-854.	3.7	228

#	ARTICLE	IF	CITATIONS
37	Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy. <i>Gastroenterology</i> , 2009, 136, 1618-1628.e2.	1.3	225
38	Chemerin Correlates with Markers for Fatty Liver in Morbidly Obese Patients and Strongly Decreases after Weight Loss Induced by Bariatric Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2892-2896.	3.6	225
39	Liver extracellular matrix in health and disease. <i>Journal of Pathology</i> , 2003, 200, 504-515.	4.5	224
40	Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. <i>Journal of Hepatology</i> , 2012, 56, 225-233.	3.7	214
41	Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. <i>Gastroenterology</i> , 2004, 126, 1323-1329.	1.3	205
42	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	205
43	Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. <i>Hepatology</i> , 2005, 41, 40-47.	7.3	204
44	Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. <i>Journal of Hepatology</i> , 1998, 28, 439-446.	3.7	189
45	Hepatocellular adenomas: Accuracy of magnetic resonance imaging and liver biopsy in subtype classification. <i>Hepatology</i> , 2011, 53, 1182-1191.	7.3	180
46	Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. <i>Hepatology International</i> , 2017, 11, 1-30.	4.2	178
47	High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study. <i>Journal of Hepatology</i> , 2009, 50, 1084-1092.	3.7	173
48	Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. <i>Diabetes Care</i> , 2021, 44, 399-406.	8.6	173
49	Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2020, 73, 252-262.	3.7	170
50	Acute Liver Cell Damage in Patients With Anorexia Nervosa: A Possible Role of Starvation-Induced Hepatocyte Autophagy. <i>Gastroenterology</i> , 2008, 135, 840-848.e3.	1.3	165
51	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2012, 56, 527-532.	3.7	165
52	Obesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN). <i>Clinical Cancer Research</i> , 2015, 21, 3522-3528.	7.0	165
53	Liver Gene Expression Signature of Mild Fibrosis in Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2005, 129, 2064-2075.	1.3	161
54	Telangiectatic adenoma: An entity associated with increased body mass index and inflammation. <i>Hepatology</i> , 2007, 46, 140-146.	7.3	157

#	ARTICLE	IF	CITATIONS
55	Porto-sinusoidal vascular disease: proposal and description of a novel entity. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 399-411.	8.1	149
56	Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. <i>Journal of Hepatology</i> , 2013, 58, 350-357.	3.7	146
57	Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. <i>Virology</i> , 2005, 332, 130-144.	2.4	145
58	Obliterative portal venopathy: Portal hypertension is not always present at diagnosis. <i>Journal of Hepatology</i> , 2011, 54, 455-461.	3.7	142
59	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 970-985.	8.1	142
60	Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPAR $\alpha$ expression. <i>Gut</i> , 2016, 65, 1882-1894.	12.1	140
61	The diagnostic accuracy of Fibroscan $\text{\textcircled{R}}$ for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. <i>Journal of Hepatology</i> , 2013, 59, 251-256.	3.7	131
62	Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: Role of biopsy. <i>Hepatology</i> , 2012, 55, 800-806.	7.3	130
63	Reversibility of hepatitis C virus-related cirrhosis. <i>Human Pathology</i> , 2004, 35, 107-112.	2.0	128
64	Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: A prospective study. <i>Hepatology</i> , 2007, 46, 380-387.	7.3	128
65	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012.	7.3	125
66	Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. <i>Journal of Hepatology</i> , 2021, 75, 284-291.	3.7	124
67	Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. <i>Liver International</i> , 2012, 32, 612-621.	3.9	123
68	How to Measure the Diagnostic Accuracy of Noninvasive Liver Fibrosis Indices: The Area Under the ROC Curve Revisited. <i>Clinical Chemistry</i> , 2008, 54, 1372-1378.	3.2	119
69	Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data. <i>PLoS ONE</i> , 2012, 7, e30325.	2.5	117
70	<i>In vivo</i> hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. <i>Journal of Pathology</i> , 2010, 221, 264-274.	4.5	109
71	Association of Adipose Tissue and Liver Fibrosis With Tissue Stiffness in Morbid Obesity: Links With Diabetes and BMI Loss After Gastric Bypass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 898-907.	3.6	107
72	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803.	1.8	105

#	ARTICLE	IF	CITATIONS
73	Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 1990-1999.	1.3	102
74	C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. <i>Journal of Hepatology</i> , 2011, 55, 660-665.	3.7	98
75	Direct and indirect evidence for the reversibility of cirrhosis. <i>Human Pathology</i> , 2006, 37, 1519-1526.	2.0	95
76	Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 1811-1822.e4.	1.3	93
77	Association between omental adipose tissue macrophages and liver histopathology in morbid obesity: Influence of glycemic status. <i>Journal of Hepatology</i> , 2009, 51, 354-362.	3.7	92
78	Genecriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	1.8	92
79	A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. <i>Hepatology</i> , 2017, 66, 555-563.	7.3	91
80	Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000075.	2.7	90
81	Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. <i>Journal of Hepatology</i> , 2015, 62, 905-912.	3.7	89
82	Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). <i>Hepatology International</i> , 2009, 3, 323-333.	4.2	88
83	Natural history of HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 211-228.	2.4	86
84	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2019, 1, 188-198.	4.9	86
85	Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 6634-6639.	7.0	84
86	Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. <i>Journal of Hepatology</i> , 2009, 51, 93-101.	3.7	83
87	Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. <i>Modern Pathology</i> , 2009, 22, 273-281.	5.5	82
88	Aberrant Expression of OX1 Receptors for Orexins in Colon Cancers and Liver Metastases: an Openable Gate to Apoptosis. <i>Cancer Research</i> , 2011, 71, 3341-3351.	0.9	79
89	Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2569-2577.	2.3	79
90	Hepatic steatosis in HIV+HCV coinfecting patients: analysis of risk factors. <i>Aids</i> , 2006, 20, 525-531.	2.2	77

#	ARTICLE	IF	CITATIONS
91	Structural and inflammatory heterogeneity in subcutaneous adipose tissue: Relation with liver histopathology in morbid obesity. <i>Journal of Hepatology</i> , 2012, 56, 1152-1158.	3.7	75
92	Heterozygous Mutations in BMP6 Pro-peptide Lead to Inappropriate Hepcidin Synthesis and Moderate Iron Overload in Humans. <i>Gastroenterology</i> , 2016, 150, 672-683.e4.	1.3	73
93	Identification of Potential Therapeutic Targets by Gene-Expression Profiling in Pancreatic Endocrine Tumors. <i>Gastroenterology</i> , 2006, 131, 1597-1610.	1.3	72
94	The PPAR $\alpha/\delta$ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2020, 10, 9330.	3.3	72
95	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	1.8	71
96	Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas. <i>Hepatology</i> , 2013, 58, 983-994.	7.3	67
97	Immunoglobulin G4 Immunostaining of Gastric, Duodenal, or Colonic Biopsies Is Not Helpful for the Diagnosis of Autoimmune Pancreatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 91-94.	4.4	66
98	Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis. <i>Gut</i> , 2015, 64, 673-683.	12.1	64
99	Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , 2009, 14, 501-511.	1.0	64
100	Pathology of the liver sinusoids. <i>Histopathology</i> , 2014, 64, 907-920.	2.9	63
101	Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2020, 10, 2565.	3.3	63
102	The FAT Score, a Fibrosis Score of Adipose Tissue: Predicting Weight-Loss Outcome After Gastric Bypass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2443-2453.	3.6	62
103	Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients. <i>Clinical Cancer Research</i> , 2012, 18, 2838-2849.	7.0	61
104	Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1170-1178.e6.	4.4	61
105	Pancreatic Endocrine Microadenomatosis in Patients With von Hippel-Lindau Disease. <i>American Journal of Surgical Pathology</i> , 2009, 33, 739-748.	3.7	60
106	Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity. <i>Gut</i> , 2017, 66, 1688-1696.	12.1	59
107	Changes in Autophagic Response in Patients with Chronic Hepatitis C Virus Infection. <i>American Journal of Pathology</i> , 2011, 178, 2708-2715.	3.8	58
108	Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category. <i>Human Pathology</i> , 2014, 45, 658-660.	2.0	58

#	ARTICLE	IF	CITATIONS
109	Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. <i>Liver International</i> , 2018, 38, 64-66.	3.9	57
110	How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?. <i>Liver International</i> , 2011, 31, 13-17.	3.9	56
111	Reversibility of hepatitis B virus cirrhosis after therapy: who and why?. <i>Liver International</i> , 2015, 35, 78-81.	3.9	55
112	Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1293-1300.	2.8	53
113	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e86-e94.	2.1	53
114	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 828-838.	3.7	52
115	Imaging Mass Spectrometry Provides Fingerprints for Distinguishing Hepatocellular Carcinoma from Cirrhosis. <i>Journal of Proteome Research</i> , 2011, 10, 3755-3765.	3.7	51
116	Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis-Perspectives From 2 Pathologists. <i>Gastroenterology</i> , 2015, 149, 1305-1308.	1.3	51
117	The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2017, 7, 17193.	3.3	50
118	Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver Agreement. <i>PLoS ONE</i> , 2015, 10, e0120299.	2.5	49
119	Diagnosis of Liver Fibrosis: Present and Future. <i>Seminars in Liver Disease</i> , 2015, 35, 166-183.	3.6	49
120	Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2010, 17, 847-856.	3.1	48
121	Response to pegylated interferon alpha2a and ribavirin in chronic hepatitis C genotype 4. <i>Journal of Medical Virology</i> , 2009, 81, 1576-1583.	5.0	47
122	Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome. <i>Oncogene</i> , 2019, 38, 3033-3046.	5.9	46
123	Current histological classification of NAFLD: strength and limitations. <i>Hepatology International</i> , 2013, 7, 765-770.	4.2	45
124	The Role of Immunohistochemistry in Idiopathic Chronic Intestinal Pseudoobstruction (CIPO). <i>American Journal of Surgical Pathology</i> , 2009, 33, 749-758.	3.7	44
125	Histological Assessment of NAFLD. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1348-1355.	2.3	44
126	Pathology Analysis Reveals That Dysplastic Pancreatic Ductal Lesions Are Frequent in Patients With Hereditary Pancreatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 206-212.	4.4	43



#	ARTICLE	IF	CITATIONS
127	Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics?. Digestive and Liver Disease, 2015, 47, 973-977.	0.9	43
128	Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2014, 12, 1724-1730.e5.	4.4	41
129	MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Scientific Reports, 2016, 6, 34935.	3.3	41
130	Cullin7: a new gene involved in liver carcinogenesis related to metabolic syndrome. Gut, 2013, 62, 911-919.	12.1	38
131	FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice. Journal of Lipid Research, 2019, 60, 1311-1322.	4.2	38
132	Hepatocellular autophagy modulates the unfolded protein response and fasting-induced steatosis in mice. American Journal of Physiology - Renal Physiology, 2016, 311, G599-G609.	3.4	37
133	Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis. Hepatology, 2021, 73, 1290-1306.	7.3	37
134	Improving performance of liver biopsy in fibrosis assessment. Journal of Hepatology, 2014, 61, 193-195.	3.7	35
135	Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2018, 73, 369-385.	2.9	35
136	SAF score and mortality in NAFLD after up to 41 years of follow-up. Scandinavian Journal of Gastroenterology, 2017, 52, 87-91.	1.5	32
137	Biological and Prognostic Relevance of Mitogen-Activated Protein Kinases in Pancreatic Adenocarcinoma. Pancreas, 2012, 41, 416-421.	1.1	30
138	Reduction of MicroRNA 122 Expression in <i>IFNL3</i> CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C. Journal of Virology, 2014, 88, 6394-6402.	3.4	29
139	Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas. Human Pathology, 2011, 42, 1702-1709.	2.0	28
140	Pathological prognostic factors in locally advanced rectal carcinoma after neoadjuvant radiochemotherapy: analysis of 113 cases. Histopathology, 2014, 65, 623-630.	2.9	28
141	Progression from cirrhosis to cancer is associated with early ubiquitin post-translational modifications: identification of new biomarkers of cirrhosis at risk of malignancy. Journal of Pathology, 2014, 234, 452-463.	4.5	28
142	Plasma Proteome to Look for Diagnostic Biomarkers of Early Bacterial Sepsis after Liver Transplantation. Anesthesiology, 2010, 112, 926-935.	2.5	28
143	Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. Neuro-Oncology, 2014, 16, 1196-1209.	1.2	27
144	Significant gene expression differences in histologically Normal liver biopsies: Implications for control tissue. Hepatology, 2008, 48, 953-962.	7.3	25

#	ARTICLE	IF	CITATIONS
145	Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. <i>Antiviral Therapy</i> , 2009, 14, 839-845.	1.0	25
146	Identifying critical steps towards improved access to innovation in cancer care: a European Cancer Organisation position paper. <i>European Journal of Cancer</i> , 2017, 82, 193-202.	2.8	25
147	TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 2466-2473.	3.9	24
148	Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. <i>PLoS ONE</i> , 2016, 11, e0155967.	2.5	23
149	Primary biliary cirrhosis: proposal for a new simple histological scoring system. <i>Liver International</i> , 2015, 35, 652-659.	3.9	22
150	Transient excess of liver fat detected by magnetic resonance imaging in women with acute fatty liver of pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 127-129.	1.3	22
151	Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis. <i>Clinical Science</i> , 2017, 131, 27-36.	4.3	22
152	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression. <i>Liver International</i> , 2018, 38, 1459-1467.	3.9	22
153	Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. <i>Hepatology</i> , 2022, 76, 456-468.	7.3	22
154	Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry. <i>Proteomics</i> , 2014, 14, 965-972.	2.2	21
155	In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin $\beta$ 4 as markers of malignant intraductal pancreatic mucinous neoplasms. <i>Pancreatology</i> , 2014, 14, 117-124.	1.1	21
156	High c-Met expression in stage II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. <i>Histopathology</i> , 2015, 67, 664-676.	2.9	21
157	Precore/Core promoter variants to predict significant fibrosis in both HBsAg positive and negative chronic hepatitis B. <i>Liver International</i> , 2015, 35, 2082-2089.	3.9	21
158	Assessment of hepatitis C: non-invasive fibrosis markers and/or liver biopsy. <i>Liver International</i> , 2009, 29, 19-22.	3.9	20
159	Fighting the bushfire in HCC trials. <i>Journal of Hepatology</i> , 2011, 55, 276-277.	3.7	20
160	Hypoxia Pathways and Cellular Stress Activate Pancreatic Stellate Cells: Development of an Organotypic Culture Model of Thick Slices of Normal Human Pancreas. <i>PLoS ONE</i> , 2013, 8, e76229.	2.5	20
161	The histone acetyltransferase hMOF promotes vascular invasion in hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 956-967.	3.9	20
162	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	4.9	20

#	ARTICLE	IF	CITATIONS
163	Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2016, 103, 495-499.	2.5	19
164	Acute extrahepatic infectious or inflammatory diseases are a cause of transient mosaic pattern on CT and MR imaging related to sinusoidal dilatation of the liver. <i>European Radiology</i> , 2016, 26, 3094-3101.	4.5	19
165	Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. <i>Lipids in Health and Disease</i> , 2017, 16, 46.	3.0	19
166	Utility and Safety of Liver Biopsy in Patients with Undetermined Liver Blood Test Anomalies after Allogeneic Hematopoietic Stem Cell Transplantation: A Monocentric Retrospective Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2523-2531.	2.0	19
167	<i>In vitro</i> , <i>In vivo</i> and <i>ex vivo</i> demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 6952-6967.	1.8	19
168	Proteomic Assessment of Markers for Malignancy in the Mucus of Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Pancreas</i> , 2012, 41, 169-174.	1.1	18
169	Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B. <i>Annals of Hepatology</i> , 2015, 14, 826-836.	1.5	18
170	ADAMTS5 deficiency protects against non-alcoholic steatohepatitis in obesity. <i>Liver International</i> , 2016, 36, 1848-1859.	3.9	18
171	Global proteomic analysis of microdissected cirrhotic nodules reveals significant biomarkers associated with clonal expansion. <i>Laboratory Investigation</i> , 2006, 86, 951-958.	3.7	17
172	Contribution of virtual biopsy to the screening of microvascular invasion in hepatocellular carcinoma: A pilot study. <i>Liver International</i> , 2018, 38, 687-694.	3.9	17
173	A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. <i>FASEB Journal</i> , 2022, 36, .	0.5	17
174	The Expression of the Hypoxia Markers CA9 and CXCR4 Is Correlated with Survival in Patients with Neuroendocrine Tumours of the Ileum. <i>Neuroendocrinology</i> , 2012, 95, 214-222.	2.5	16
175	Histologic and noninvasive estimates of liver fibrosis. <i>Clinical Liver Disease</i> , 2015, 6, 5-8.	2.1	16
176	Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort). <i>Hepatology</i> , 2018, 68, 1534-1548.	7.3	16
177	Cirrhosis Regression and Subclassification. <i>Surgical Pathology Clinics</i> , 2013, 6, 295-309.	1.7	15
178	Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates. <i>JHEP Reports</i> , 2021, 3, 100381.	4.9	15
179	Distal intramural and tumor spread in the mesorectum after neoadjuvant radiochemotherapy in rectal cancer: about 124 consecutive patients. <i>Human Pathology</i> , 2016, 52, 164-172.	2.0	14
180	Does Early Antiretroviral Treatment Prevent Liver Fibrosis in HIV/HCV-Coinfected Patients?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 234-236.	2.1	13

#	ARTICLE	IF	CITATIONS
181	A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses. <i>Infectious Agents and Cancer</i> , 2012, 7, 16.	2.6	13
182	Accumulation of Intrahepatic TNF- $\alpha$ -Producing NKp44+ NK Cells Correlates With Liver Fibrosis and Viral Load in Chronic HCV Infection. <i>Medicine (United States)</i> , 2016, 95, e3678.	1.0	13
183	Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome. <i>Gut</i> , 2015, 64, 1498-1500.	12.1	12
184	An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials. <i>Diagnostics</i> , 2020, 10, 643.	2.6	12
185	Functional role of ADAMTS5 in adiposity and metabolic health. <i>PLoS ONE</i> , 2018, 13, e0190595.	2.5	12
186	Harmony in liver fibrosis. <i>Journal of Hepatology</i> , 2010, 52, 313-314.	3.7	11
187	SCG10 Expression on Activation of Hepatic Stellate Cells Promotes Cell Motility Through Interference with Microtubules. <i>American Journal of Pathology</i> , 2010, 177, 1791-1797.	3.8	11
188	High serum level of alpha-fetoprotein in focal nodular hyperplasia of the liver. <i>Pathology International</i> , 2011, 61, 491-494.	1.3	11
189	AdipoScan: A Novel Transient Elastography-Based Tool Used to Non-Invasively Assess Subcutaneous Adipose Tissue Shear Wave Speed in Obesity. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 2401-2413.	1.5	11
190	Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 713-722.e3.	4.4	9
191	Diagnosis of sinusoidal obstruction syndrome by positron emission tomography/computed tomography: Report of two cases treated by defibrotide. <i>Hepatology</i> , 2014, 60, 1789-1791.	7.3	8
192	Vascular Disorders. , 2018, , 636-672.		8
193	Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 952-966.	3.7	8
194	Relevance of Adipose Tissue Stiffness Evaluated by Transient Elastography (AdipoScan $\text{®}$ ) in Morbidly Obese Patients before Bariatric Surgery. <i>Physics Procedia</i> , 2015, 70, 1264-1268.	1.2	7
195	Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. <i>Biomedicines</i> , 2022, 10, 699.	3.2	7
196	Somatostatin Receptor Subtype 2 Expression and Somatostatin Receptor Scintigraphy Positivity in Pancreatic Serous Cystadenomas. <i>Pancreas</i> , 2015, 44, 672-674.	1.1	6
197	Well-differentiated hepatocellular neoplasm of uncertain malignant potential. reply. <i>Human Pathology</i> , 2015, 46, 635-636.	2.0	6
198	At similar weight loss, dietary composition determines the degree of glycemic improvement in diet-induced obese C57BL/6 mice. <i>PLoS ONE</i> , 2018, 13, e0200779.	2.5	6

#	ARTICLE	IF	CITATIONS
199	Fibrogenesis Marker PRO-C3 Is Higher in Advanced Liver Fibrosis and Improves in Patients Undergoing Bariatric Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1356-e1366.	3.6	6
200	A new feature of the MYH9-related syndrome: Chronic transaminase elevation. <i>Hepatology</i> , 2013, 57, 1288-1289.	7.3	5
201	Role of ADAMTS13 in diet-induced liver steatosis. <i>Molecular Medicine Reports</i> , 2017, 16, 1451-1458.	2.4	5
202	Porto-sinusoidal vascular disease. Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFL), and ERN-rare liver. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 447-451.	1.5	5
203	Liver fibrosis: Screening is not staging. <i>Journal of Hepatology</i> , 2009, 50, 1268-1269.	3.7	4
204	N-Butyl-2-Cyanoacrylate in Gastric Varices: A Cause for Recurrent Sepsis. <i>American Journal of Gastroenterology</i> , 2013, 108, 1937-1938.	0.4	4
205	Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease. , 2016, , 223-247.		4
206	Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study). <i>Journal of Hepatology</i> , 2011, 55, 234-235.	3.7	3
207	Role of hepatic HCV RNA level on the severity of chronic hepatitis C and response to antiviral therapy. <i>Journal of Clinical Virology</i> , 2012, 53, 43-47.	3.1	3
208	Tumors of the liver. , 2012, , 1223-1249.e5.		2
209	AdipoScan - A novel transient elastography based tool to assess subcutaneous adipose tissue shear wave speed in morbidly obese patients. , 2014, , .		2
210	Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: A retrospective clinical pathological study. <i>Digestive and Liver Disease</i> , 2015, 47, 296-302.	0.9	2
211	Cellular and Molecular Techniques. , 2018, , 88-110.		2
212	Microcirculatory changes in the liver of patients with refractory ascites and their relationship with diabetes and alcohol. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	1.6	2
213	Tumors of the liver. , 2017, , 1272-1298.e7.		1
214	Hepatocellular adenoma: Different entities for a single lesion. <i>Annals of Hepatology</i> , 2014, 13, 450-451.	1.5	0
215	Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders. , 2019, , 245-274.		0
216	ATU-09 - Obeticholic acid treatment is associated with improved collagen morphometry in patients with primary biliary cholangitis. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
217	Fifty years of impact on liver pathology: a history of the Gnomes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 191-200.	2.8	0
218	Hepatocellular adenoma: different entities for a single lesion. Annals of Hepatology, 2014, 13, 450-1.	1.5	0
219	Non-Invasive Markers of Liver Fibrosis: Useful or Useless?. , 0, , 1-5.		0